Back

Rationale and design of the CADENCE trial: evaluating sotatercept in Cpc-PH secondary to HFpEF

1 September 2025 (10:00 - 10:45)
Organised by: Logo
Congress Presentation Part of: New perspectives in cardiology (4) - Pharmacotherapy for heart failure (1) Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Alessia Urbinati

New York (United States of America)

8 More presentations in this session

Presentation thumbnail
Presentation thumbnail
Mr E. Boada Lincango (A Coruna, ES)
Abstract Slides Video
Presentation thumbnail
Doctor B. Muk (Budapest, HU)
Abstract
Presentation thumbnail
Doctor P. Amornritvanich (Bangkok, TH)
Abstract Slides Video
Presentation thumbnail
Doctor F. Banfi-Bacsardi (Budapest, HU)
Abstract Slides Video

Access the full session

Session thumbnail
New perspectives in cardiology (4) - Pharmacotherapy for heart failure (1)

The Event

Event poster

ESC Congress 2025

1 September 2025 10:00 CET
You may be interested in
thumbnail
Congress Presentation
Efficacy and safety of selexipag in pulmonary arterial hypertension (PAH) patients with and without significant cardiovascular (CV) comorbidities
3 September 2019
thumbnail
Congress Presentation
SERENADE: Macitentan in heart failure with preSERved ejEction fractioN and pulmonAry vascular DiseasE
21 May 2022
thumbnail
Congress Presentation
The pre-HFpEF entity: a window of opportunity to prevent and halt the progression to heart failure with preserved ejection fraction (HFpEF)
29 June 2021
thumbnail
Congress Session
Emerging interventional procedures in heart failure and pulmonary hypertension
20 May 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources